NovoCure Ltd. (NVCR)
14.18
-0.17
(-1.18%)
USD |
NASDAQ |
Jan 12, 16:00
14.18
0.00 (0.00%)
After-Hours: 20:00
NovoCure Research and Development Expense (Quarterly): 54.03M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| LivaNova Plc | 48.58M |
| Perspective Therapeutics, Inc. | 19.56M |
| InfuSystem Holdings, Inc. | -- |
| Xtant Medical Holdings, Inc. | 0.634M |
| VolitionRX Ltd. | 2.022M |